LXR-A Antibody
| Code | Size | Price |
|---|
| PSI-5577-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-5577-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
LXR-A Antibody: LXRA, LXR-a, RLD-1, LXRA, Oxysterols receptor LXR-alpha, Liver X receptor alpha
Application Note:
LXR-A antibody can be used for detection of LXR-A by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in rat samples; Immunohistochemistry in rat samples and Immunofluorescence in rat samples. All other applications and species not yet tested.
Antibody validated: Western Blot in rat samples; Immunohistochemistry in rat samples and Immunofluorescence in rat samples. All other applications and species not yet tested.
Background:
LXR-A Antibody: LXR-A belongs to the Liver X Receptor family that encodes highly homologous transcription factors. Like the highly homologous LXR-B, LXR-A forms heterodimers with the retinoic acid receptor RXRalpha, function as sensors for cellular oxysterols which when activated, increase the expression of genes that control sterol and fatty acid metabolism and homeostasis. Recent experiments have indicated that the LXRs can also modulate both innate and adaptive immune responses. Human and mouse tumors produce LXR ligands that inhibit CCR7 expression on maturing dendritic cells (DCs), thereby allowing tumor immunoescape. In mouse models, it was shown that ablating LXR-A signaling led to an immune-mediated strong inhibition of tumor growth, suggesting that manipulation of this pathway may be a viable anti-cancer approach.
Background References:
- Willy PJ, Umesono K, Ong ES, et al. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev.1995; 9:1033-45.
- Edwards PA, Kennedy MA, and Mak PA. LXRs; Oxysterol-activated nuclear receptors that regulate genes controlling lipid homeostasis. Vasc. Pharmacol.2002; 38:249-56.
- Bensinger SJ and Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature2008; 454:470-7.
- Villablanca EJ, Raccosta L, Zhou D, et al. Tumor-mediated liver X receptor-a activation inhibits CC chemokine reeptor-7 expression on dendritic cells and dampens antitumor responses. Nature Med.2010; 16:98-106.
Buffer:
LXR-A Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
LXR-A antibody was raised against a 15 amino acid synthetic peptide from near the amino terminus human LXR-A.
The immunogen is located within amino acids 50 - 100 of LXR-A.
The immunogen is located within amino acids 50 - 100 of LXR-A.
NCBI Gene ID #:
10062
NCBI Official Name:
nuclear receptor subfamily 1, group H, member 3
NCBI Official Symbol:
NR1H3
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 44, 49 kDa
Observed: 46 kDa
Observed: 46 kDa
Protein Accession #:
NP_005684
Protein GI Number:
194294517
Purification:
LXR-A Antibody is affinity chromatography purified via peptide column.
Research Area:
Innate Immunity
Swissprot #:
Q13133
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | LXR-A Peptide | PSI-5577P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|